Navigation Links
Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
Date:11/10/2011

SAN DIEGO, Nov. 10, 2011 /PRNewswire/ -- Synteract, Inc., a full-service, global contract research organization (CRO), and MediciNova, Inc., a publicly traded biopharmaceutical company focused on novel, small-molecule therapeutics for the treatment of serious diseases, will team up to support the American Lung Association (ALA) in California in their annual Fight For Air Walk through team participation and donations. The two companies also are working together on a Phase 2 trial studying MediciNova's compound MN-221 to combat asthma and chronic obstructive pulmonary disease (COPD).

(Logo: http://photos.prnewswire.com/prnh/20111108/MM02925LOGO)

The American Lung Association Fight For Air Walk is a statewide event held at venues throughout California to increase awareness and raise funds for the Lung Association's fight for clean air and healthy lungs. Synteract and MediciNova will each field walking teams on Sunday, Nov. 13th at Embarcadero Park South in San Diego in recognition of Lung Cancer Awareness Month and COPD Awareness Month, both in November. Synteract exceeded its original team fundraising goal and has already doubled the amount. The company-wide initiative includes bake sales and other activities that support fundraising. The three-mile walk will bring co-workers, friends and families together in support of the work of the American Lung Association in California.

"Synteract and MediciNova are pleased to be able to help the American Lung Association in its fundraising efforts and education of the community about such debilitating diseases as asthma and COPD," said Ali Sadighian, vice president, business development at Synteract. "With the support of our team walkers, we are participating in ALA's efforts to save lives today and keep America healthy tomorrow."

MediciNova, Inc. acquires and develops novel, small-molecule therapeutics for the treatment of serious diseases with a commercial focus on the U.S. market. MediciNova's lead drug candidate, MN-221, is an intravenous treatment for patients suffering from acute exacerbations of asthma and COPD. Currently MediciNova's MN-221, a highly selective beta(2)-adrenergic receptor agonist, is in a Phase 2 clinical trial for acute exacerbations of asthma. The study, being conducted with Synteract, continues to enroll patients through December, involves 15 sites across the U.S. and 200 patients.

Those who are interested in participating in the walk or donating to the association can contact Synteract representative Joanna Dojillo at 760-268-8296 or the American Lung Association in California at www.lungusa.org/california.

About Synteract, Inc.

Synteract is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: http://www.synteract.com; (760) 268.8200.

About MediciNova, Inc.

MediciNova, Inc. is a publicly traded biopharmaceutical company acquiring and developing novel, small-molecule therapeutics for the treatment of serious diseases with a commercial focus on the U.S. market.  Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential, and patent coverage of commercially adequate scope.  MediciNova's pipeline includes six clinical-stage compounds to be monetized. For more information, visit www.medicinova.com

CONTACT:

Beth Walsh
Clearpoint Agency, for Synteract
beth@clearpointagency.com
858-724-2500


'/>"/>
SOURCE Synteract, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
2. GlaxoSmithKline and the University of Edinburgh Agree to Collaborative Partnership for Drug Discovery
3. Endress+Hauser and Finesse Solutions Form Strategic Partnership - Swiss Process Automation Provider Invests in US Biotech Company
4. Vaccine Partnering Terms and Agreements
5. XECAN and Trimble Partner to Deliver ThingMagic Powered RFID Oncology Solution
6. Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs
7. ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development
8. Merlin Nexus and New Leaf Venture Partners Continue to Contest Proposed $56 Million Acquisition of Icagen by Pfizer
9. New Partnership Bolsters Relivs Access to Plant Biotech Research
10. GeneSeek Partners With Researchers to Combat E. coli
11. Quanterix and STRATEC Announce Strategic Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a fundamental challenge ... to full-size tissues, bones, even whole organs to implant in people to treat ... deep into the developing tissue. , Current bioengineering techniques, including 3-D printing, ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT ... (the "Company" or "Propellon"), a start-up created by ... anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive capital, ... program. The seed funding enables Propellon to accelerate ... the Company for financing and/or entering a strategic ...
Breaking Biology Technology:
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/2/2017)... -- Australian stem cell and regenerative medicine company, ... agreement with the Monash Lung Biology Network, a consortia ... Department of Pharmacology at Monash University, Melbourne ... support the use of Cymerus™ mesenchymal stem cells (MSCs) ... is a chronic, long term lung condition recognised by ...
Breaking Biology News(10 mins):